Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Lung Neoplasms 4Neoplasms 2Solid Tumors 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 2a 1Lymphoma, Large-Cell, Anaplastic 1Lung Diseases 1Genomic Instability 1Central Nervous System Neoplasms 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Bone Neoplasms 1Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer 1

Interventions

Magnetic Resonance Spectroscopy 6Biopsy 6X-Rays 5Specimen Handling 5Phantoms, Imaging 5Nuclear Medicine Department, Hospital 4Cisplatin 3Carboplatin 3tazemetostat 2selpercatinib 2larotrectinib 2erdafitinib 2entrectinib 2ensartinib 2cabozantinib 2Topotecan 2Temozolomide 2Surveys and Questionnaires 2Radiation 2LY3023414 2Gemcitabine 2Etoposide 2Cyclophosphamide 2ulixertinib 1tipifarnib 1pegfilgrastim 1palbociclib 1olaparib 1niraparib 1mirdametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Central Nervous System Neoplasms × alectinib × 90 days × Clear all
NCT04774718 2026-06-04

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

Hoffmann-La Roche

Phase 1/2 Recruiting
42 enrolled
CNS

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡